This phase I trial is evaluating how safe and tolerable a targeted therapy (talazoparib) is in combination with radionuclide therapy (177Lu-DOTA-Octreotate) in people with metastatic pancreatic neuroendocrine cancer.
This trial is treating patients with pancreatic neuroendocrine tumours.
This is a systemic and radiation therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
All eligible participants will receive 4 cycles of 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) every 8 weeks, with the last 3 cycles being combined with talazoparib. Talazoparib will be administered in escalating doses, orally, daily during days 2-6 of these cycles.
Recruiting Hospitals Read More